Editas Medicine, Inc. (NASDAQ:EDIT) has been given a consensus rating of “Buy” by the six research firms that are covering the company, MarketBeat reports. Two research analysts have rated the stock with a hold recommendation, three have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $31.38.

A number of equities analysts recently commented on EDIT shares. Cowen and Company reiterated a “buy” rating on shares of Editas Medicine in a research report on Wednesday, March 15th. Zacks Investment Research upgraded shares of Editas Medicine from a “sell” rating to a “hold” rating in a research report on Tuesday, March 28th. Jefferies Group LLC reiterated a “buy” rating and issued a $35.00 target price on shares of Editas Medicine in a research report on Wednesday, February 15th. J P Morgan Chase & Co set a $32.00 target price on shares of Editas Medicine and gave the stock a “hold” rating in a research report on Wednesday, March 8th. Finally, Vetr upgraded shares of Editas Medicine from a “buy” rating to a “strong-buy” rating and set a $27.14 target price on the stock in a research report on Monday, March 20th.

Editas Medicine (NASDAQ EDIT) traded up 0.44% during mid-day trading on Tuesday, reaching $16.14. The company had a trading volume of 195,035 shares. The firm has a 50-day moving average price of $17.50 and a 200 day moving average price of $19.03. Editas Medicine has a 12-month low of $12.43 and a 12-month high of $32.67. The firm’s market capitalization is $657.37 million.

Editas Medicine (NASDAQ:EDIT) last issued its earnings results on Monday, May 15th. The company reported ($0.85) EPS for the quarter, missing analysts’ consensus estimates of ($0.62) by $0.23. The business had revenue of $0.68 million during the quarter, compared to analysts’ expectations of $1 million. Editas Medicine had a negative return on equity of 63.29% and a negative net margin of 1,864.00%. Editas Medicine’s revenue for the quarter was down 16.0% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.80) EPS. Analysts expect that Editas Medicine will post ($2.74) EPS for the current year.

COPYRIGHT VIOLATION NOTICE: This news story was posted by American Banking News and is the property of of American Banking News. If you are viewing this news story on another domain, it was copied illegally and republished in violation of U.S. and international copyright and trademark laws. The correct version of this news story can be read at https://www.americanbankingnews.com/2017/06/13/editas-medicine-inc-edit-receives-average-recommendation-of-buy-from-analysts.html.

In other news, insider Gerald Frank Cox acquired 4,000 shares of the firm’s stock in a transaction on Friday, June 2nd. The shares were purchased at an average price of $14.15 per share, for a total transaction of $56,600.00. Following the completion of the transaction, the insider now owns 4,000 shares of the company’s stock, valued at $56,600. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Kevin Bitterman sold 1,000,000 shares of the business’s stock in a transaction dated Monday, May 22nd. The shares were sold at an average price of $17.00, for a total transaction of $17,000,000.00. The disclosure for this sale can be found here.

Institutional investors have recently added to or reduced their stakes in the stock. Russell Investments Group Ltd. purchased a new position in Editas Medicine during the fourth quarter worth about $284,000. State Street Corp boosted its position in Editas Medicine by 2.4% in the fourth quarter. State Street Corp now owns 105,167 shares of the company’s stock worth $1,708,000 after buying an additional 2,476 shares during the last quarter. Norges Bank purchased a new position in Editas Medicine during the fourth quarter worth about $1,479,000. Trexquant Investment LP purchased a new position in Editas Medicine during the first quarter worth about $542,000. Finally, Cim Investment Mangement Inc. purchased a new position in Editas Medicine during the first quarter worth about $572,000. Hedge funds and other institutional investors own 67.36% of the company’s stock.

About Editas Medicine

Editas Medicine, Inc is a genome editing company. It is engaged in treating patients with genetically defined diseases by correcting their disease-causing genes. It operates through developing and commercializing genome editing technology segment. It is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR) technology.

Receive News & Ratings for Editas Medicine Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Editas Medicine Inc. and related companies with MarketBeat.com's FREE daily email newsletter.